Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Source: nct - Country: Argentina,Germany,Taiwan, Province of China,Czech Republic,Belgium,Australia,Spain,Canada,France
nct
Update Il y a 5 ans
Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment period in participants with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).
Country
Argentina
,
Australia
,
Belgium
,
Bosnia and Herzegovina
,
Bulgaria
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Korea, Republic of
,
Malaysia
,
Portugal
,
Romania
,
Serbia
,
Singapore
,
South Africa
,
Spain
,
Taiwan, Province of China
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Satavaptan Dose-Ranging Study in the Prevention of Ascites
The primary objective is to determine the optimal dose or range of doses of SR121463B for the reduction in recurrence of ascites, when used concomitantly with a standard dose regimen of spironolactone. The secondary objective was to determine the tolerability of different fixed doses of SR121463B in cirrhotic ascites, over a 12-week treatment period. This SPA study is followed by a single-blind, placebo-controlled, 40 weeks long-term safety extension (ExSPA). The first extension is followed by another long-term study (PASCCAL-1).
Country
Argentina
,
Australia
,
Belgium
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Italy
,
Spain
,
Taiwan, Province of China
,
organs
None
Specialty
None
Closed trial
More information
1